Alzheimer Disease
📧 Sign up to get email alerts when something new happens for Alzheimer Disease.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-10-11FDA Approved: MEMANTINE HYDROCHLORIDE — Original Application (Vitruvias Therapeutics, Inc.)
FDA approved a generic memantine hydrochloride product under an Original Application (ANDA) from Vitruvias Therapeutics, Inc. for the treatm…
-
CLINICAL_TRIALS trial_result · 2022-10-03Clinical Trial Update: A Study of Semorinemab in Patients With Moderate Alzheimer's Disease [Phase 2]
Phase 2 study evaluating semorinemab in patients with moderate Alzheimer's disease has completed and results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update evaluating the safety and efficacy of AstroStem for Alzheimer's disease.
-
FDA approval · 2022-09-26FDA Approved: MEMANTINE HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved a generic memantine hydrochloride product from Camber Pharmaceuticals under its Original Application, intended for treating…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. [Phase 2, Phase 3]
A multicenter Phase 2/3 study evaluating potential disease-modifying treatments for individuals at risk for or with dominantly inherited ear…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD) [Phase 2]
An extension study of ABBV-8E12 in early Alzheimer’s disease (Phase 2) was terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2022-09-14Clinical Trial Update: Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease [Phase 2]
Phase 2 clinical trial investigating a traditional Chinese medicine 'Smart Soup' for cognition and behavior regulation in Alzheimer's diseas…
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type [Phase 3]
Phase 3 trial updating on efficacy, safety, and tolerability of AVP-786 for agitation in dementia of the Alzheimer's type (Alzheimer's disea…
-
CLINICAL_TRIALS trial_result · 2022-09-09Clinical Trial Update: Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) [Phase 2]
Phase 2 clinical trial update on tau brain imaging in typical and atypical Alzheimer's disease.
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment [NA]
Completed clinical trial studying adaptive neuroplasticity in individuals with mild cognitive impairment and Alzheimer's disease; results po…
-
CLINICAL_TRIALS trial_result · 2022-08-30Clinical Trial Update: A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease [Phase 2]
Phase 2 clinical trial update for LY3303560 in early symptomatic Alzheimer's disease; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2022-08-26Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease [Phase 2]
A Phase 2 clinical trial evaluating ABBV-8E12 for early Alzheimer's disease has completed and results were posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-08-25Clinical Trial Update: Tdap and Biomarkers of Alzheimer's Disease [Phase 1, Phase 2]
Phase 1 and Phase 2 trial update for a Tdap-based approach investigating biomarkers in late-onset Alzheimer’s disease.
-
CLINICAL_TRIALS trial_result · 2022-08-22Clinical Trial Update: The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression [EARLY_Phase 1]
Phase 1 study update for INCREASE exploring delaying onset of Alzheimer's symptomatic expression; study completed with posted results.
-
FDA approval · 2022-08-19FDA Approved: AMYVID — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for AMYVID (florbetapir F-18) from Eli Lilly and Company, an imaging agent used to assess beta-a…
-
CLINICAL_TRIALS trial_result · 2022-08-08Clinical Trial Update: Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients [Phase 2]
A Phase 2 clinical trial evaluated metabolic cofactor supplementation in patients with Alzheimer's disease and Parkinson's disease; study st…
-
EMA withdrawal · 2022-08-01EMA Application withdrawn: Aduhelm (aducanumab) — Biogen Netherlands B.V.
EMA withdrew the application for Aduhelm (aducanumab) by Biogen Netherlands B.V. for Alzheimer’s disease.
-
CLINICAL_TRIALS trial_result · 2022-07-27Clinical Trial Update: Improvisational Movement for People With Memory Loss and Their Caregivers [NA]
A completed clinical trial evaluating improvisational movement for people with memory loss and their caregivers has posted results.
-
CLINICAL_TRIALS trial_result · 2022-07-14Clinical Trial Update: ANAVEX2-73 for Treatment of Early Alzheimer's Disease [Phase 2, Phase 3]
Clinical trials for ANAVEX2-73 in early Alzheimer's disease completed Phase 2 and Phase 3.
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease [Phase 4]
A Phase 4 trial update assessing the efficacy and safety of memantine combined with sodium oligomannate in patients with moderate to severe …
-
FDA approval · 2022-07-01FDA Approved: TAUVID — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for TAUVID (flortaucipir F-18) from Eli Lilly, updating its labeling and/or indication. TAUVID is a …
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease [NA]
A completed clinical trial investigating the impact of Photobiomodulation on biomarkers of Alzheimer’s disease.
-
EMA approval · 2022-06-30EMA Authorised: Memantine ratiopharm (memantine hydrochloride) — Ratiopharm GmbH
Memantine ratiopharm has been authorised for use in its indicated therapeutic area.
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: Benfotiamine in Alzheimer's Disease: A Pilot Study [Phase 2]
A Phase 2 pilot study assessing benfotiamine in Alzheimer's disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-16Clinical Trial Update: A Study of Gantenerumab in Participants With Mild Alzheimer Disease [Phase 3]
Phase 3 clinical trial update for gantenerumab in mild Alzheimer's disease completed; results posted in 2022.